Drug Target Review2025-09-03T09:00:57
Researchers at Mount Sinai have identified three antibodies that target mpox and prevent severe disease in vivo. The work positions A35-specific antibodies as candidates for therapeutic development.
Already a member? Sign in
By highlighting cutting-edge research and its practical applications, Drug Target Review enables readers to make decisions that accelerate innovation, translate discoveries into therapies, and create tangible benefits for patients worldwide.
By becoming a member you join a connected and collaborative community driving the industry forward. Member benefits include:
2026-07-31T06:00:00Z
Contributor Dr Davinder Ramsingh, Drug Target Review
2026-06-30T14:00:00
Sponsored by Analytik Jena GmbH + Co. KG
2024-02-01T11:52:50
Sponsored by Leica Microsystems
2023-12-11T10:49:07
Sponsored by Leica Microsystems
2023-01-19T15:38:17
Sponsored by Cell Signaling Technology
2024-02-01T12:06:43
Sponsored by Leica Microsystems
Site powered by Webvision Cloud